Q2 profit jumps 249% as revenue rises 46%; stamp duty case remains open
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts more than Nifty Microcap 250 and 6.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 consolidated revenue rose 45.9% to Rs 610.45 crore and profit after tax rose 248.8% to Rs 71.47 crore. Half-year revenue rose 42.5% to Rs 1,146.25 crore and profit rose 121.8% to Rs 147.61 crore. The review highlighted a Rs 57.46 crore contingent stamp duty and penalty exposure; Rs 2.04 crore was provided and a court challenge is pending. Prior figures were restated. The finance chief exits October 30 and Vibha Thakkar starts October 31.
Strong earnings may support the stock, but the Rs 57.46 crore disputed stamp duty exposure and finance chief change may offset some gains.